Evidence map›Paper›PMID 33781142›Full record

Trial reportTherapeutic advances in respiratory disease

The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease.

Nawar Diar Bakerly, Dominy Browning, Isabelle Boucot, Jodie Crawford, Sheila McCorkindale, Norman Stein, John P New

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01551758 (A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01551758 phase3completednot on this map

A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) Compared With the Existing COPD Maintenance Therapy Alone in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorGlaxoSmithKlineRan2012 to 2015Enrolled2,802ConditionsPulmonary Disease, Chronic ObstructiveArmsFF/VI, Existing Maintenance Therapy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Nawar Diar BakerlyDepartment of Respiratory Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK.
Dominy BrowningRespiratory Research and Development, GlaxoSmithKline plc., Brentford, Middlesex, UK.
Isabelle BoucotGlobal Respiratory Therapy Area, GlaxoSmithKline plc., Brentford, Middlesex, UK.
Jodie CrawfordClinical Statistics, GlaxoSmithKline plc., Stockley Park West, Uxbridge, Middlesex, UK.
Sheila McCorkindaleNIHR Clinical Research Network Greater Manchester, Citylabs 1.0, Manchester, UK.
Norman SteinManchester Academic Health Sciences Centre, University of Manchester, Citylabs 1.0, Manchester.
John P NewDepartment of Respiratory Medicine, Salford Royal NHS Foundation Trust, Salford, UK.
GlaxoSmithKline (United Kingdom) · GBHealth Sciences Centre · CANIHR Clinical Research Network · GBSalford Royal NHS Foundation Trust · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD) was a randomised controlled trial evaluating the effectiveness and safety of initiating fluticasone furoate/vilanterol (FF/VI) 100/25 µg

methodsHRU and interventions were determined from patients' electronic health records. Annual rates of on-treatment all-cause and COPD-related secondary care contacts (SCCs) and primary care contacts (PCCs) for FF/VI

resultsLeast-squares (LS) mean annual rates of all-cause (9.81 DISCUSSION: In patients with COPD and exacerbation history, FF/VI may represent a less costly alternative to current therapies.GlaxoSmithKline plc. study HZC115151; ClinicalTrials.gov NCT01551758.

Indexed as

AdultAgedAged, 80 and overAndrostadienesBenzyl AlcoholsChlorobenzenesDrug CombinationsElectronic Health RecordsFemaleHealth Care CostsHospitalizationHumansLength of StayMaleMiddle AgedPatient Acceptance of Health CareAndrostadienesBenzyl AlcoholsChlorobenzenesDrug Combinationsfluticasone furoate-vilanterol trifenatateCOPDeffectivenessfluticasone furoatehealthcare resource utilisationusual carevilanterol

Identifiers

PMID33781142
PMCPMC8013671
OpenAlexW3143595100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.